Tag: Diabetes: Type II
Canagliflozin Delays Increase in Certain CV Biomarkers in T2DM
Canagliflozin may reduce CV, heart failure risk over two years versus placebo in older patients with T2DM
Diabetes Symptoms Appear to Spread Via Prion-Like Mechanism
Injections in mice led to symptoms of the disease, researchers report
Moderate Drinking May Be Protective Against Diabetes
Wine appears to provide the most protective benefit, researchers say
Fasting Plasma Glucose, HbA1c Linked to Alzheimer’s in T2DM
Independent associations for FPG coefficient of variation and HbA1c CV in patients with T2DM
Visceral/Subcutaneous Fat Ratio Predicts CVD in T2DM
Ratio of visceral to subcutaneous fat significantly linked to incident, recurrent cardiovascular disease
Earlier Menopause Independently Tied to Higher Risk of T2DM
With menopause before 40, risk is 3.7 times greater compared to late menopause, researchers find
Electronic Messaging Intervention Cuts Cardiovascular Risk in T2DM
Intervention effective for reducing cardiovascular risk in patients with type 2 diabetes
NT-proBNP Improves Heart Failure Prediction in T2DM
Meaningful improvement in five-year risk-predictive performance with addition of NT-proBNP
Coronary CT Angiography Ups Prediction of MACE in T2DM
Addition of CCTA-detected obstructive coronary artery disease to risk factors ups prediction of MACE
Therapeutic Inertia in 19 Percent With T2DM, HbA1c ≥8 Percent
HbA1c values of 8.0 to 9.9, >10 percent, diabetes duration ≥20 years linked to tx intensification
